Membranous Nephropathy that First Presented in Pregnancy
نویسندگان
چکیده
منابع مشابه
Membranous Nephropathy
A forty-three year old female applied for a $200,000 ten year decreasing term policy. She admitted a history of "kidney disorder" on the application. She was not being treated or having any symptoms but stated that she was under observation. A routine paramed exam showed height 5’4", weight 140 lbs, and blood pressure 110/70. The BCP was normal. The HOS showed 210 mg/dl proteinuria. A reflex de...
متن کاملMembranous Nephropathy
Forty-one patients with a nephrotic syndrome and biopsy-proven membranous nephropathy were administered a 3 to 6-month course of cyclosporine (CsA; 4 to 5 mg/kg per day). Differential solute clearances were used to evaluate glomerular function before and after therapy. CsA lowered median proteinuria by 56%, from 7.3 to 3.2 g/24 h (P < 0.0001). Corresponding mean increments in serum albumin, imm...
متن کاملMembranous Nephropathy
Membranous nephropathy (MN), a very common cause of nephrotic syndrome, is a glomerulopathy defined histopathologically by the presence of immune complexes on the extracapillary side of the glomerular basement membrane (GBM). Idiopathic membranous nephropathy (IMN) is an antibody-mediated glomerular disease with no defined etiology, histologically characterized by uniform thickening of glomerul...
متن کاملRituximab in membranous nephropathy: is it a first-line treatment?
Rituximab, a B cell–depleting anti-CD20 chimeric monoclonal antibody, is Food and Drug Administration approved in the United States for the treatment of certain lymphomas, rheumatoid arthritis, and granulomatous and microscopic polyangiitis. It has been used additionally in a wide variety of glomerular disorders including lupus nephritis, IgA nephropathy, minimal change disease and focal segmen...
متن کاملRituximab in primary membranous nephropathy: first-line therapy, why not?
The ideal treatment of patients with primary membranous nephropathy (MN) and persistent nephrotic syndrome (NS) is still a matter of debate. This is a major issue since these patients may progress to end-stage kidney disease (ESKD) in 5-10 years. Steroids, alkylating agents, and calcineurin inhibitors have been suggested to achieve NS remission and prevent ESKD in this population. Treatment ben...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Internal Medicine
سال: 2013
ISSN: 0918-2918,1349-7235
DOI: 10.2169/internalmedicine.52.0645